NEXIGN
(AfricaCom virtual event) --Nexign (a part of ICS Holding LLC), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, today announced that it has expanded its product portfolio with a new solution-driven business model - Nexign Instant BSS . It is a well-defined pre-integrated package incorporating a BSS stack covering mobile prepaid services and the best practices of project delivery and support. This solution enables CSPs to speed up decision-making process and start new business in four months.
Nexign Instant BSS solution is designed to respond to the rapidly changing market requirements with a light-weight, easily extendable billing solution enabling a quick start of mobile telecoms business and providing CSPs with an opportunity to grow with strong foundation for further expansion.
“Nexign Instant BSS allows mid-sized CSPs and MVNO to rapidly launch mobile services without escalating complexity of BSS systems, enabling operators to add extra functionality for the evolving business. The solution is built on the basis of Nexign’s 28 year-experience in transformation projects of different size and complexity. While CSPs often have to choose between full-scale transformation and quick start, we are ready to share our best practices with the customers to help them simplify project implementation and accelerate business growth,” said Andrey Gulidin, Chief Commercial Officer of Nexign.
Nexign Instant BSS reduces the decision-making process by providing CSPs with a clear understanding of the project scope and calendar. Apart from technological capabilities, Nexign customers get access to a comprehensive knowledge base, including the methodology for transparent project management and the options for solution extension. This enables fast and efficient project execution, helping CSPs to achieve true ownership of the product, avoid vendor lock-in and enrich the solution according to their needs.
“Nexign’s Instant BSS can help CSPs accelerate their deployment and go-to market which is key to improving competitiveness especially in emerging markets. The Nexign Instant BSS’s open architecture and transparent implementation offer CSPs the flexibility to manage and maintain the solution in-house or externally. This adaptability, alongside the ability to adjust the solution in step with rapidly changing business environment will be an important consideration for CSPs and MVNOs,” said John Abraham, Principal Analyst of Analysys Mason.
Visit Nexign’s virtual booth at AfricaCom on November 9–12, 2020 for more information about Nexign’s products and services.
About Nexign
Nexign , a part of Intellectual Computer Systems Holding (ICS Holding) and a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, has been delivering value-driven, high-performance solutions since 1992.
As communications service providers become digital service providers, Nexign accelerates their transformation through engineering excellence and agile products that facilitate revenue-stream diversification.
Headquartered in St. Petersburg, Nexign employs 1,800 people in Russia, the Commonwealth of Independent States, the Middle East, Africa, Southeast Asia and LATAM.
Please visit the website and follow Nexign on Twitter , Facebook and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110006164/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom